Literature DB >> 22175902

Expression of carbonic anhydrase IX in genitourinary and adrenal tumours.

Daniel P Donato1, Matthew T Johnson, Ximing J Yang, Debra L Zynger.   

Abstract

AIMS: High expression of carbonic anhydrase IX (CAIX) is reported for clear cell renal cell carcinoma (RCC), with a paucity of data for non-renal genitourinary or adrenal tumours. This study investigated the immunohistochemical expression of CAIX throughout the genitourinary tract and adrenal gland. METHODS AND
RESULTS: High expression in the renal cortex was restricted to clear cell, papillary and clear cell papillary RCC and carcinoid. Core biopsies of clear cell RCC were consistently positive. Positivity within the urothelial tract was seen in urothelial carcinoma including squamous, small-cell, sarcomatoid and adenomatous differentiation and clear cell adenocarcinoma. Signet ring and plasmacytoid variants of urothelial carcinoma were negative. Phaeochromocytoma, adrenal cortical adenoma, seminoma, yolk sac tumour, choriocarcinoma, Leydig cell tumour and prostatic adenocarcinoma were predominately negative, with variable reactivity in adrenal cortical carcinoma, embryonal carcinoma, teratoma and Sertoli cell tumour.
CONCLUSIONS: Carbonic anhydrase IX is a sensitive marker for clear cell RCC in core biopsies. However, other genitourinary or adrenal tumours that can have a clear cell appearance including urothelial, squamous cell, clear cell adeno and adrenal cortical carcinoma and Sertoli cell tumour express CAIX. Knowledge of expression overlap between these entities may prevent incorrect interpretation of immunohistochemical results, particularly if limited tissue is available.
© 2011 Blackwell Publishing Limited.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22175902     DOI: 10.1111/j.1365-2559.2011.04074.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  5 in total

1.  PET/CT imaging of renal cell carcinoma with (18)F-VM4-037: a phase II pilot study.

Authors:  Baris Turkbey; Maria L Lindenberg; Stephen Adler; Karen A Kurdziel; Yolanda L McKinney; Juanita Weaver; Cathy D Vocke; Miriam Anver; Gennady Bratslavsky; Philip Eclarinal; Gideon Kwarteng; Frank I Lin; Nana Yaqub-Ogun; Maria J Merino; W Marston Linehan; Peter L Choyke; Adam R Metwalli
Journal:  Abdom Radiol (NY)       Date:  2016-01

2.  New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.

Authors:  Kiril Trpkov; Ondrej Hes; Sean R Williamson; Anthony J Gill; Adebowale J Adeniran; Abbas Agaimy; Reza Alaghehbandan; Mahul B Amin; Pedram Argani; Ying-Bei Chen; Liang Cheng; Jonathan I Epstein; John C Cheville; Eva Comperat; Isabela Werneck da Cunha; Jennifer B Gordetsky; Sounak Gupta; Huiying He; Michelle S Hirsch; Peter A Humphrey; Payal Kapur; Fumiyoshi Kojima; Jose I Lopez; Fiona Maclean; Cristina Magi-Galluzzi; Jesse K McKenney; Rohit Mehra; Santosh Menon; George J Netto; Christopher G Przybycin; Priya Rao; Qiu Rao; Victor E Reuter; Rola M Saleeb; Rajal B Shah; Steven C Smith; Satish Tickoo; Maria S Tretiakova; Lawrence True; Virginie Verkarre; Sara E Wobker; Ming Zhou
Journal:  Mod Pathol       Date:  2021-03-04       Impact factor: 8.209

Review 3.  Histopathological determinants of tumor resistance: a special look to the immunohistochemical expression of carbonic anhydrase IX in human cancers.

Authors:  G Ilardi; N Zambrano; F Merolla; M Siano; S Varricchio; M Vecchione; G De Rosa; M Mascolo; S Staibano
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

4.  Prognostic value of intratumoral carbonic anhydrase IX expression in testicular germ cell tumors.

Authors:  Katarina Kalavska; Zuzana Cierna; Michal Chovanec; Martina Takacova; Daniela Svetlovska; Viera Miskovska; Jana Obertova; Patrik Palacka; Jan Rajec; Zuzana Sycova-Mila; Katarina Machalekova; Karol Kajo; Stanislav Spanik; Jozef Mardiak; Pavel Babal; Silvia Pastorekova; Michal Mego
Journal:  Oncol Lett       Date:  2017-02-14       Impact factor: 2.967

5.  GLUT3/SLC2A3 Is an Endogenous Marker of Hypoxia in Prostate Cancer Cell Lines and Patient-Derived Xenograft Tumors.

Authors:  John M Ryniawec; Matthew R Coope; Emily Loertscher; Vignesh Bageerathan; Diogo de Oliveira Pessoa; Noel A Warfel; Anne E Cress; Megha Padi; Gregory C Rogers
Journal:  Diagnostics (Basel)       Date:  2022-03-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.